DK0879282T3 - Immunterapi ved anvendelse af cytotoksiske T-lymfocytter (CTL) - Google Patents

Immunterapi ved anvendelse af cytotoksiske T-lymfocytter (CTL)

Info

Publication number
DK0879282T3
DK0879282T3 DK97900365T DK97900365T DK0879282T3 DK 0879282 T3 DK0879282 T3 DK 0879282T3 DK 97900365 T DK97900365 T DK 97900365T DK 97900365 T DK97900365 T DK 97900365T DK 0879282 T3 DK0879282 T3 DK 0879282T3
Authority
DK
Denmark
Prior art keywords
molecule
patient
ctl
lymphocytes
cytotoxic
Prior art date
Application number
DK97900365T
Other languages
Danish (da)
English (en)
Inventor
Hans Josef Stauss
Original Assignee
Imp College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9600878.4A external-priority patent/GB9600878D0/en
Priority claimed from GBGB9623471.1A external-priority patent/GB9623471D0/en
Application filed by Imp College Innovations Ltd filed Critical Imp College Innovations Ltd
Application granted granted Critical
Publication of DK0879282T3 publication Critical patent/DK0879282T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK97900365T 1996-01-17 1997-01-17 Immunterapi ved anvendelse af cytotoksiske T-lymfocytter (CTL) DK0879282T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9600878.4A GB9600878D0 (en) 1996-01-17 1996-01-17 Immunotherapy
GBGB9623471.1A GB9623471D0 (en) 1996-11-12 1996-11-12 Immunotherapy
PCT/GB1997/000118 WO1997026328A1 (fr) 1996-01-17 1997-01-17 Immunotherapie utilisant des lymphocytes t cytotoxiques (ctl)

Publications (1)

Publication Number Publication Date
DK0879282T3 true DK0879282T3 (da) 2003-10-20

Family

ID=26308471

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97900365T DK0879282T3 (da) 1996-01-17 1997-01-17 Immunterapi ved anvendelse af cytotoksiske T-lymfocytter (CTL)

Country Status (11)

Country Link
US (1) US6805861B2 (fr)
EP (1) EP0879282B1 (fr)
JP (1) JP4767371B2 (fr)
AT (1) ATE244300T1 (fr)
AU (1) AU1394497A (fr)
CA (1) CA2243235C (fr)
DE (1) DE69723230T2 (fr)
DK (1) DK0879282T3 (fr)
ES (1) ES2203782T3 (fr)
PT (1) PT879282E (fr)
WO (1) WO1997026328A1 (fr)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT879282E (pt) 1996-01-17 2003-11-28 Imp College Innovations Ltd Imunoterapia utilizando linfocitos t citotoxicos (ctl)
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
JP4422903B2 (ja) 1998-07-31 2010-03-03 株式会社癌免疫研究所 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原
US6407063B1 (en) * 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
AU5992999A (en) 1998-10-02 2000-04-26 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
DE69839970D1 (de) * 1998-11-10 2008-10-16 Univ Rochester Methoden zu herstellung von genbanken
AU2736400A (en) 1999-01-27 2000-08-18 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
EP1118661A1 (fr) * 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut Bibliotheques du recepteur de cellule T
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
US7572631B2 (en) * 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US6797514B2 (en) * 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU2001252998A1 (en) 2000-03-28 2001-10-08 University Of Rochester Methods of producing a library and methods of selecting polynucletides
EP1280889B1 (fr) * 2000-05-11 2007-08-29 Baylor Research Institute Compositions et procédés de production de cellules présentatrices d'antigènes
EP1227822A2 (fr) * 2000-05-25 2002-08-07 Xcyte Therapies, Inc. Methodes de retablissement ou de stimulation de l'immuno-surveillance des cellules t suite a l'immunosupression induite par voie naturelle ou artificielle
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US20030143647A1 (en) * 2001-09-24 2003-07-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Anticancer vaccine and diagnostic methods and reagents
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
CA2525519A1 (fr) * 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation et isolement de lymphocytes t specifiques de l'antigene
EP1663308A1 (fr) * 2003-09-22 2006-06-07 Xcyte Therapies, Inc Compositions et methodes pour accelerer une guerison hematologique
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
CA2580412A1 (fr) * 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Preparations comprenant des recepteurs cellulaires t et methodes d'utilisation de ces preparations
DE602004019215D1 (de) 2004-10-02 2009-03-12 Immatics Biotechnologies Gmbh Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden
WO2007044033A2 (fr) 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Récepteur non restreint par le cmh cloné de l'antigène spécifique de tumeur muc1 pour applications thérapeutiques et diagnostiques
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
ATE512160T1 (de) 2005-04-26 2011-06-15 Immatics Biotechnologies Gmbh T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen
JP5079697B2 (ja) * 2005-08-05 2012-11-21 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハー 抗原特異的ｔ細胞の生成方法
ATE440107T1 (de) 2005-09-05 2009-09-15 Immatics Biotechnologies Gmbh Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe
PT1806358E (pt) 2005-09-05 2010-05-28 Immatics Biotechnologies Gmbh Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii
EP2565201B1 (fr) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research Peptides de liaison WT1 HLA de classe II et compositions et procédés comprenant ceux-ci
CA2645766A1 (fr) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Peptides wt1 immunogenes et leurs methodes d'utilisation
US20080131415A1 (en) 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
EP1932537A1 (fr) * 2006-12-12 2008-06-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) l'expression de recepteurs des lymphocytes t transgeniques dans lymphocytes lak-t
CA2694805C (fr) 2007-07-27 2014-09-09 Immatics Biotechnologies Gmbh Nouveaux epitopes immunogenes destines a l'immunotherapie
PT2660248E (pt) 2007-07-27 2015-10-12 Immatics Biotechnologies Gmbh Nova imunoterapia para tumores neuronais e cerebrais
ES2554981T3 (es) 2008-03-27 2015-12-28 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra tumores neuronales y cerebrales
NO2119726T3 (fr) 2008-05-14 2015-05-23
WO2010011994A2 (fr) 2008-07-25 2010-01-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Polypeptides et leurs utilisations
PT2172211E (pt) 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
US8697854B2 (en) 2008-11-24 2014-04-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh High affinity T cell receptor and use thereof
US8467973B2 (en) * 2009-07-28 2013-06-18 Promising Future, Llc Pairing processes for preparing alloreactive cytotoxic T cells
GB0917094D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
TWI777194B (zh) 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一）
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
EP3172325B1 (fr) 2014-07-22 2023-06-28 The University of Notre Dame du Lac Constructions moléculaires et utilisations correspondantes
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh New peptides and combinations of peptides used in immunotherapy against ovarian cancer and other types of cancer
EP4321172A2 (fr) 2015-07-06 2024-02-14 immatics biotechnologies GmbH Nouveaux peptides et combinaison de peptides destinés à être utilisés en immunothérapie contre le cancer de l' sophage et d'autres cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
CN116375797A (zh) 2016-03-01 2023-07-04 伊玛提克斯生物技术有限公司 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
MY197258A (en) 2016-04-06 2023-06-08 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
TW202304970A (zh) 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
MA47367B1 (fr) 2017-01-27 2023-06-28 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
EA201992416A1 (ru) 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
MA49122A (fr) 2017-04-10 2021-03-24 Immatics Biotechnologies Gmbh Peptides et combinaisons de peptides destinés à être utilisés en immunothérapie anticancéreuse
US11427614B2 (en) 2017-04-10 2022-08-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
TW201906859A (zh) 2017-07-07 2019-02-16 德商英麥提克生物技術股份有限公司 用於肺癌（包括 nsclc、sclc 和其他癌症）免疫治療的新型肽和肽組合物
WO2019007974A1 (fr) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du poumon, y compris le cpnpc, le cppc et d'autres cancers
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US20230002730A1 (en) * 2018-05-18 2023-01-05 Children's National Medical Center Improved targeted t-cell therapy
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
CN109294995B (zh) * 2018-09-30 2020-08-04 北京鼎成肽源生物技术有限公司 一种rfft1细胞
CN110408657B (zh) * 2018-09-30 2021-03-16 北京鼎成肽源生物技术有限公司 一种afft1细胞的构建方法
US20220056092A1 (en) 2018-12-11 2022-02-24 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
CA3132840A1 (fr) 2019-03-08 2020-09-17 Obsidian Therapeutics, Inc. Compositions d'anhydrase carbonique humaine 2 et procedes de regulation accordable
MX2021010831A (es) 2019-03-08 2021-12-15 Obsidian Therapeutics Inc Composiciones de ligando del cumulo de diferenciación 40 (cd40l) y métodos para regulación ajustable.
AU2020290522A1 (en) 2019-06-12 2022-01-20 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation
US20220267398A1 (en) 2019-06-12 2022-08-25 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
WO2021040736A1 (fr) 2019-08-30 2021-03-04 Obsidian Therapeutics, Inc. Compositions à base de car cd19 tandem et méthodes d'immunothérapie
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
MX2022008415A (es) 2020-01-08 2022-08-08 Obsidian Therapeutics Inc Composiciones y metodos para la regulacion ajustable de la transcripcion.
EP4090365A1 (fr) 2020-01-15 2022-11-23 Immatics Biotechnologies GmbH Protéines de liaison à l'antigène se liant de manière spécifique à prame
EP4168053A1 (fr) 2020-06-22 2023-04-26 Obsidian Therapeutics, Inc. Compositions et méthodes de régulation accordable de nucléases de cas
WO2022060806A1 (fr) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions et procédés pour l'expression de récepteurs antigéniques chimériques anti-bcma ayant une il15 régulée par petites molécules dans des cellules t
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
WO2022184805A1 (fr) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Protéines de liaison à l'antigène se liant spécifiquement à des peptides antigéniques du sars-cov-2 en un complexe avec une protéine du complexe majeur d'histocompatibilité
AU2022270361A1 (en) 2021-05-05 2023-11-16 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
AU2022318257A1 (en) 2021-07-27 2024-02-08 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding ct45

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61176529A (ja) 1985-02-01 1986-08-08 Shuji Sawaki 特異的キラ−ｔ細胞の製造方法
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5081029A (en) 1985-09-25 1992-01-14 Oncogen Methods of adoptive immunotherapy for treatment of aids
EP0257962A3 (fr) 1986-08-29 1989-05-24 Becton, Dickinson and Company Méthode de traitement de sang périphérique pour améliorer l'immunothérapie par cellule tueuse activée par une lymphokine
ES2056054T3 (es) * 1986-09-19 1994-10-01 Oncogen Uso de linfocitos t activados para preparar una composicion farmaceutica para el tratamiento del sida.
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
JPH0279969A (ja) 1988-09-19 1990-03-20 Shigeyoshi Fujimoto 細胞障害性ｔ細胞誘導及び活性化の方法
EP0415666A1 (fr) 1989-08-29 1991-03-06 Takeda Chemical Industries, Ltd. Composition pour la culture de cellules humaines et son utilisation
JPH05502369A (ja) 1989-09-14 1993-04-28 セルコ、インコーポレイテッド 養子免疫療法に用いられる生体外増殖リンパ性細胞の製造方法
EP0453560B1 (fr) 1989-11-13 1999-05-26 Massachusetts Institute Of Technology Localisation et caracterisation du gene tumoral de wilms
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
EP0553186B1 (fr) 1990-09-28 1999-09-01 Immunex Corporation Methode servant a produire des lymphocytes t cytotoxiques t h?-independants
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
JPH07102131B2 (ja) 1991-07-15 1995-11-08 日本石油株式会社 ヒトリンパ球の癌細胞に対する傷害活性を高める方法
AU3435293A (en) * 1992-01-21 1993-08-03 Ludwig Institute For Cancer Research Method for determining cytolytic T cell precursors
US5314813A (en) 1992-02-19 1994-05-24 Scripps Research Institute Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
US5731160A (en) * 1992-05-26 1998-03-24 Rijksuniversiteit Leiden Induction of antigen specific T-lymphocyte responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines
CA2158281A1 (fr) 1993-03-15 1994-09-29 Jay A. Berzofsky Cellules dentritiques revetues de peptide, agents immunogenes
DE69433115T2 (de) * 1993-06-21 2004-04-01 Brigham And Women's Hospital, Boston Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien
AU7478394A (en) 1993-08-06 1995-02-28 Cytel Corporation Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
EP0738390B1 (fr) 1994-01-06 2003-04-02 Telik, Inc. Substituts de cibles et batteries de reference ameliorees
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
IL112969A (en) * 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
EP0784482A2 (fr) * 1994-06-07 1997-07-23 The Regents Of The University Of Minnesota Procedes d'inhibition des reponses des lymphocytes t specifiques a un antigene
PT879282E (pt) 1996-01-17 2003-11-28 Imp College Innovations Ltd Imunoterapia utilizando linfocitos t citotoxicos (ctl)
JPH10218093A (ja) 1997-02-05 1998-08-18 Suzuki Motor Corp 船外機
JP4422903B2 (ja) 1998-07-31 2010-03-03 株式会社癌免疫研究所 癌抑制遺伝子ｗｔ１の産物に基づく癌抗原
MXPA01003344A (es) 1998-09-30 2004-04-21 Corixa Corp Composiciones y metodos para inmunoterapia especifica de wt1.

Also Published As

Publication number Publication date
CA2243235A1 (fr) 1997-07-24
ES2203782T3 (es) 2004-04-16
WO1997026328A1 (fr) 1997-07-24
JP2000503656A (ja) 2000-03-28
DE69723230D1 (de) 2003-08-07
US6805861B2 (en) 2004-10-19
ATE244300T1 (de) 2003-07-15
PT879282E (pt) 2003-11-28
EP0879282A1 (fr) 1998-11-25
JP4767371B2 (ja) 2011-09-07
CA2243235C (fr) 2010-08-10
DE69723230T2 (de) 2004-05-27
AU1394497A (en) 1997-08-11
EP0879282B1 (fr) 2003-07-02
US20020090362A1 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
DK0879282T3 (da) Immunterapi ved anvendelse af cytotoksiske T-lymfocytter (CTL)
MD970009A (en) Methods for inducing T cells tolerance to donor tissues or organs
MX9800145A (es) Vectores y virales de tejido especifico.
ATE310077T1 (de) Erzeugung von hämatopoietischen zellen aus multipotenten neuronalen stammzellen
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
TR199800912T2 (xx) T�m�r a��s� ve a��n�n haz�rlanmas� i�in usul.
BR9306345A (pt) Métodos para suprimir a habilidade de células-t de um mamífero de proliferar e para suprimir resposta imune composições para uso na supressão da capacidade de células-t de proliferarem e na supressão de resposta imune
EP0809437A4 (fr) Thiols utilises pour favoriser la croissance de cellules hematopoietiques parentes
ATE210149T1 (de) Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden
EP0690125A3 (fr) Procédé de culture d'induction de lymphocytes T cytotoxiques capable de détruire des cellules tumorales
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
PT941329E (pt) Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
AU5323396A (en) Methods of treating inflammation and compositions therefor
TR199701520T1 (xx) Ac�n�n iyile�tirilmesi i�in analjesik bile�ikleri �reten h�cre soyu.
MX9703535A (es) Linfocitos t dirigidos.
AU685540B2 (en) T cell receptor variable transcripts as disease related markers
SE9402370D0 (sv) Use of IGF-I
AU1123001A (en) Compositions and methods for preventing and treating transplant rejection
IL132310A0 (en) Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
MX9803610A (es) Utilizacion de flupirtina para la profilaxis y la terapia de enfermedades que van a compañadas de un deterioro del sistema celular hermatopoyetico.
DE69807672D1 (de) Von milchsäure abgeleitete butyrat-prodrugs
NZ333006A (en) Non-transformant immortalized avian cell lines derived from avian fibroblasts and epithelial cells there are immortalised by the SV40 T+t gene in the dependence on the MTI promoter
DK0883406T3 (da) Anvendelse af IL-7 til behandling af autoimmune sygdomme og især insulinafhængig diabe-tesmellitus i særdeleshed
DK0863866T3 (da) Butyrat-prodrugs afledt af mælkesyre
DK0789591T3 (da) Fremgangsmåde til identifikation af individer, som lider af en celleabnormitet